ObvioHealth

ObvioHealth

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

ObvioHealth, founded in 2017 and based in Orlando, USA, is a private company operating in the Digital Health sector. It has developed the ObvioGo® platform, an end-to-end digital solution for designing and managing decentralized and hybrid clinical trials. The company targets pharmaceutical, biotech, medical device, and CRO clients, offering a suite of tools to reduce trial timelines, improve data quality, and enhance patient compliance. ObvioHealth is in a revenue-generating stage, leveraging a platform-based business model to scale its operations.

Digital Health

Technology Platform

ObvioGo® is an enterprise digital platform for designing and managing decentralized and hybrid clinical trials. It is an integrated suite offering no-code study design, digital recruitment, eConsent with eSignature, logistics management, ePRO/eCOA, virtual visits, and real-time data capture/monitoring, all built for compliance and scalability.

Funding History

2
Total raised:$17.5M
Series A$12.5M
Seed$5M

Opportunities

The rapid adoption of decentralized and hybrid trial models, driven by demands for patient diversity, accessibility, and faster timelines, presents a massive growth opportunity.
Expansion into new geographic markets and deepening integrations with wearable devices and real-world data sources offer additional avenues for platform growth and value creation.

Risk Factors

Intense competition from other DCT platform vendors and integrated CROs poses a significant market risk.
Execution risks related to platform integration, user adoption, and maintaining stringent, evolving global regulatory compliance for digital data could impact client trust and commercial success.

Competitive Landscape

ObvioHealth competes in a crowded market for decentralized clinical trial solutions. Key competitors include pure-play DCT platform providers like Medable and Science 37, as well as the digital trial arms of large Contract Research Organizations (CROs) such as IQVIA and Parexel. Its differentiation hinges on its position as an integrated, end-to-end platform aiming to simplify sponsor operations.